Follow
Elamin H Elbasha
Elamin H Elbasha
Distinguished Scientist, Merck Research Laboratories, Merck & Co., Inc
Verified email at merck.com
Title
Cited by
Cited by
Year
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
H Razavi, AC ElKhoury, E Elbasha, C Estes, K Pasini, T Poynard, ...
Hepatology 57 (6), 2164-2170, 2013
6142013
Model for assessing human papillomavirus vaccination strategies
EH Elbasha, EJ Dasbach, RP Insinga
Emerging infectious diseases 13 (1), 28, 2007
5872007
Impact of vaccinating boys and men against HPV in the United States
EH Elbasha, EJ Dasbach
Vaccine 28 (42), 6858-6867, 2010
2762010
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV …
RP Insinga, EJ Dasbach, EH Elbasha
BMC infectious diseases 9, 1-26, 2009
2732009
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature
RP Insinga, EJ Dasbach, EH Elbasha
Pharmacoeconomics 23, 1107-1122, 2005
2502005
Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease
EJ Dasbach, EH Elbasha, RP Insinga
Epidemiologic reviews 28 (1), 88-100, 2006
2172006
Role of incidence function in vaccine-induced backward bifurcation in some HIV models
O Sharomi, CN Podder, AB Gumel, EH Elbasha, J Watmough
Mathematical Biosciences 210 (2), 436-463, 2007
1992007
On endogenous growth: the implications of environmental externalities
EH Elbasha, TL Roe
Journal of Environmental Economics and Management 31 (2), 240-268, 1996
1681996
A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations
AB Gumel, EA Iboi, CN Ngonghala, EH Elbasha
Infectious Disease Modelling 6, 148-168, 2021
1582021
Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits
EH Elbasha, AB Gumel
Bulletin of mathematical biology 68, 577-614, 2006
1392006
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance
RP Insinga, G Perez, CM Wheeler, LA Koutsky, SM Garland, S Leodolter, ...
Cancer Epidemiology, Biomarkers & Prevention 20 (2), 287-296, 2011
1342011
Vaccination against multiple HPV types
EH Elbasha, AP Galvani
Mathematical biosciences 197 (1), 88-117, 2005
1342005
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives
RP Insinga, EJ Dasbach, EH Elbasha, KL Liaw, E Barr
Cancer Epidemiology Biomarkers & Prevention 16 (4), 709-715, 2007
1252007
Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation
RP Insinga, EJ Dasbach, EH Elbasha, A Puig, LM Reynales-Shigematsu
Vaccine 26 (1), 128-139, 2007
1232007
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
RP Insinga, G Perez, CM Wheeler, LA Koutsky, SM Garland, S Leodolter, ...
Cancer epidemiology, biomarkers & prevention 19 (6), 1585-1594, 2010
1082010
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
EJ Dasbach, RP Insinga, EH Elbasha
BJOG: An International Journal of Obstetrics & Gynaecology 115 (8), 947-956, 2008
1022008
An ex post economic impact assessment of planted forages in West Africa
E Elbasha, PK Thornton, G Tarawali
ILRI (aka ILCA and ILRAD), 1999
97*1999
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women
RP Insinga, EJ Dasbach, EH Elbasha, KL Liaw, E Barr
Infectious agents and cancer 2, 1-10, 2007
862007
Deadweight loss of bacterial resistance due to overtreatment
EH Elbasha
Health economics 12 (2), 125-138, 2003
822003
A multi-type HPV transmission model
EH Elbasha, EJ Dasbach, RP Insinga
Bulletin of mathematical biology 70, 2126-2176, 2008
802008
The system can't perform the operation now. Try again later.
Articles 1–20